RIMeL - IJLaM, Vol. 5, N. 3-S1, 2009 (MAF Servizi srl ed.)

Index

• Index

Proceedings

• 003 - 2009 Program
• 025 - Plenary index
• 026 - Personalized Medicine between research and clinical practice: the role of Laboratory Medicine
• 033 - Technological and organizational innovations applied to molecular predictive medicine
• 040 - The molecular diagnosis applied to clinical oncology
• 046 - Molecular pathogenesis of different histotypes of thyroid carcinoma: the role of NBS1 gene in the pathogenesis of solid tumors induced by ionizing radiation
• 052 - Reference Intervals in Endocrinology: the case of TSH
• 062 - The benefits of TSH Reflex according to the Endocrinologist and the Laboratory
• 065 - TSH Reflex: the problems
• 071 - The puzzle Legionella
• 075 - Laboratory diagnosis of Legionnaires’ disease
• 081 - Legionella: risk communication and responsability
• 087 - Epidemiology of legionella infections: the experience in Campania Region
• 090 - Component Resolved Diagnosis (CRD): in-vitro definition of allergic patient’s profile
• 096 - What the Component Resolved Diagnosis cannot tell us yet
• 100 - The Component resolved diagnosis in paediatric allergy diagnosis
• 103 - Renal failure
• 104 - Standardization of the measurements of creatinine and new markers of renal insufficiency: an update
• 105 - Glomerular filtration rate measurement: from equations to report consensus
• 106 - Urinary Albumin Excretion in chronic kidney disease: critical issues in measurement and reporting
• 107 - Biomarkers: state of the art and perspectives
• 108 - Can we personalize drug therapy in colorectal cancer patients?
• 109 - High Sensitivity C-reactive protein and other markers of cardiovascular inflammation: from bench to prove of efficacy
• 110 - Non invasive diagnosis of gastrointestinal disorders: GastroPanel and Fibrotest
• 111 - Clinical risk: from problem to opportunity
• 112 - FMEA-FMECA: a risk management’s strument for critical processes
• 113 - Pre-analytical phase: Risk Management and Risk Assessment in a Hospital Laboratory
• 114 - Risk management triggers in postanalytical phase
• 115 - Pharmacogenetics: promise or reality?
• 116 - Pharmacogenetics and clinical oncology: a new deal for personalized therapies
• 118 - Pharmacogenetics and Diabetes
• 119 - Pharmacogenetics of oral anticoagulant therapy
• 120 - POSTER Abstract
• 214 - Author index
• Index